89bio, Inc.
ETNB
$8.18
-$0.17-2.04%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.70M | 10.50M | 8.57M | 9.85M | 7.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.01M | 151.94M | 53.44M | 57.28M | 41.21M |
| Operating Income | -122.01M | -151.94M | -53.44M | -57.28M | -41.21M |
| Income Before Tax | -118.10M | -148.87M | -47.84M | -51.58M | -36.37M |
| Income Tax Expenses | 257.00K | 204.00K | 134.00K | 97.00K | 3.87M |
| Earnings from Continuing Operations | -118.35M | -149.07M | -47.97M | -51.68M | -40.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -118.35M | -149.07M | -47.97M | -51.68M | -40.24M |
| EBIT | -122.01M | -151.94M | -53.44M | -57.28M | -41.21M |
| EBITDA | -122.00M | -151.93M | -53.42M | -57.27M | -41.19M |
| EPS Basic | -1.02 | -1.39 | -0.48 | -0.54 | -0.50 |
| Normalized Basic EPS | -0.65 | -0.87 | -0.30 | -0.35 | -0.30 |
| EPS Diluted | -1.02 | -1.39 | -0.48 | -0.54 | -0.50 |
| Normalized Diluted EPS | -0.65 | -0.87 | -0.30 | -0.35 | -0.30 |
| Average Basic Shares Outstanding | 115.96M | 107.08M | 99.83M | 95.85M | 80.70M |
| Average Diluted Shares Outstanding | 115.96M | 107.08M | 99.83M | 95.85M | 80.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
